(Q34291868)

1 August 2017

title

Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel(TM). (English)

1 reference

1 August 2017

1 reference

Alka Madaan

1

1 reference

1 August 2017

Pratibha Singh

2

1 reference

1 August 2017

Anshumali Awasthi

3

1 reference

1 August 2017

Ritu Verma

4

1 reference

1 August 2017

Anu T Singh

5

1 reference

1 August 2017

Manu Jaggi

6

1 reference

1 August 2017

Shiva Kant Mishra

7

1 reference

1 August 2017

Sadanand Kulkarni

8

1 reference

1 August 2017

Hrishikesh Kulkarni

9

1 reference

1 August 2017

publication date

24 July 2012

1 reference

Clinical and Translational Oncology

1 August 2017

published in

1 reference

1 August 2017

volume

15

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

26-32

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-012-0883-2

1 August 2017

exact match

0 references

cites work

Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Paclitaxel: a review of adverse toxicities and novel delivery strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Paclitaxel prodrugs: toward smarter delivery of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Cytoskeletal disassembly and cell rounding promotes adipogenesis from ES cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Multi-functional polymeric nanoparticles for tumour-targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Size-dependent endocytosis of gold nanoparticles studied by three-dimensional mapping of plasmonic scattering images

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Radiosensitization of paclitaxel, etanidazole and paclitaxel+etanidazole nanoparticles on hypoxic human tumor cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Biology of nitric oxide signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Drug delivery and transport to solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Therapeutic nanoparticles for drug delivery in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0883-2

Nanomedicine: techniques, potentials, and ethical implications

21 January 2018

1 reference

12 December 2020

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

1 reference

12 December 2020

Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.

1 reference

12 December 2020

Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel

1 reference

12 December 2020

10.1007/S12094-012-0883-2

Identifiers

DOI

1 reference

1 August 2017

1 reference